These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35120916)

  • 1. Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Kanneganti M; Singal AG
    Gastroenterology; 2022 May; 162(6):1772-1774. PubMed ID: 35120916
    [No Abstract]   [Full Text] [Related]  

  • 2. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults.
    Marengo A; Jouness RI; Bugianesi E
    Clin Liver Dis; 2016 May; 20(2):313-24. PubMed ID: 27063271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease".
    Jamialahmadi O; Bianco C; Pelusi S; Romeo S; Valenti L
    J Hepatol; 2021 Jun; 74(6):1494-1496. PubMed ID: 33676949
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease - who and how?
    Teng ML; Tan DJH; Ng CH; Huang DQ
    Clin Mol Hepatol; 2023 Apr; 29(2):404-407. PubMed ID: 36916168
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter to the Editor: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in Patients With Nonalcoholic Fatty Liver Disease.
    Yang NB; Li GX; Chu JG; Wang YJ
    Hepatology; 2020 Jun; 71(6):2172-2173. PubMed ID: 31849080
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter to the Editor: Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Steatohepatitis Cirrhosis and Diabetes: Insufficient for Individual Management.
    Feng Z; Rong P; Wang W
    Hepatology; 2020 Jul; 72(1):361-362. PubMed ID: 31903611
    [No Abstract]   [Full Text] [Related]  

  • 9. NAFLD and HCC: Time to Bridge the Gap.
    Cholankeril G; Kanwal F
    Hepatology; 2021 Nov; 74(5):2336-2338. PubMed ID: 34164841
    [No Abstract]   [Full Text] [Related]  

  • 10. NAFLD as a risk factor for HCC: new rules of engagement?
    Masuzaki R; Karp SJ; Omata M
    Hepatol Int; 2016 Jul; 10(4):533-4. PubMed ID: 27146835
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Zhang C; Wang P; Li Y; Huang C; Ni W; Chen Y; Shi J; Chen G; Hu X; Ye M; Duan S; Wang K
    Anat Rec (Hoboken); 2019 Feb; 302(2):193-200. PubMed ID: 30312023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatocellular carcinoma].
    Czauderna C; Marquardt JU; Galle PR; Wörns MA
    Internist (Berl); 2017 May; 58(5):469-479. PubMed ID: 28386626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From NASH to HCC: current concepts and future challenges.
    Anstee QM; Reeves HL; Kotsiliti E; Govaere O; Heikenwalder M
    Nat Rev Gastroenterol Hepatol; 2019 Jul; 16(7):411-428. PubMed ID: 31028350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis.
    Phan J; Ng V; Sheinbaum A; French S; Choi G; El Kabany M; Durazo F; Saab S; Tong M; Busuttil R; Han SH
    J Clin Gastroenterol; 2019 Apr; 53(4):309-313. PubMed ID: 29912756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
    Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.
    Lindenmeyer CC; McCullough AJ
    Clin Liver Dis; 2018 Feb; 22(1):11-21. PubMed ID: 29128051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter to the Editor: The Association Between Diabetes and Hepatocellular Carcinoma in Patients With Cirrhosis Caused by Nonalcoholic Fatty Liver Disease.
    Tantai X; Liu N; Wang J
    Hepatology; 2020 Jul; 72(1):363-364. PubMed ID: 31904864
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatocellular carcinoma screening in NAFLD: The paradox of nearly half the cases arising in non-cirrhotic low risk patients.
    Machado MV
    Ann Hepatol; 2023; 28(3):101101. PubMed ID: 37116966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.